![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial
|
|
|
Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
Avy Violari,1 Rosa Bologna,2 Nagalingeswaran Kumarasamy,3
Jose Henrique Pilotto,4 Annemie Hendrickx,5 Thomas N Kakuda,6
Erkki Lathouwers,5 Magda Opsomer,5 Tom Van de Casteele5 and
Frank L Tomaka6
1Chris Hani Baragwanath Hospital, Johannesburg, South Africa; 2Helios Salud, Buenos Aires, Argentina; 3YRGCARE Medical Centre, VHS, Chennai, India; 4Hospital Geral De Nova Iguacu,
Rio De Janeiro, Brazil; 5Janssen Infectious Diseases BVBA, Beerse, Belgium;
6Janssen Research & Development LLC, Titusville, NJ, USA
![IAS1.gif](../images/071113/071113-3/IAS1.gif)
![IAS2.gif](../images/071113/071113-3/IAS2.gif)
![IAS3.gif](../images/071113/071113-3/IAS3.gif)
![IAS4.gif](../images/071113/071113-3/IAS4.gif)
![IAS5.gif](../images/071113/071113-3/IAS5.gif)
![IAS6.gif](../images/071113/071113-3/IAS6.gif)
![IAS7.gif](../images/071113/071113-3/IAS7.gif)
![IAS8.gif](../images/071113/071113-3/IAS8.gif)
![IAS9.gif](../images/071113/071113-3/IAS9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|